Clair N. Hayes

Hiroshima, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 154 publications

A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment.

A Case of Unresectable Hepatocellular Carcinoma Responding to Durvalumab Plus Tremelimumab after Lenvatinib Treatment.

Journal: Internal medicine (Tokyo, Japan)

Published: August 19, 2026

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

A Study on the Association Between Treatment Response to Atezolizumab Plus Bevacizumab Combination Therapy for Advanced Hepatocellular Carcinoma and Gut Microbiota.

Journal: Microorganisms

Published: March 08, 2026

Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".

Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".

Journal: Journal of gastroenterology

Published: February 26, 2026

Specimen quality shapes the actionable genomic landscape in comprehensive cancer genomic profiling.

Specimen quality shapes the actionable genomic landscape in comprehensive cancer genomic profiling.

Journal: NPJ genomic medicine

Published: February 25, 2026

Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.

Durvalumab and tremelimumab combination therapy achieved remarkable response in primary hepatic undifferentiated carcinoma with high PD-L1 expression.

Journal: Clinical journal of gastroenterology

Published: December 08, 2025

Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Efficacy and Safety of Second-Line Lenvatinib After First-Line Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 18, 2025

Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma.

Anlotinib plus penpulimab: a new contender in first-line therapy for unresectable hepatocellular carcinoma.

Journal: Journal of gastrointestinal oncology

Published: October 11, 2025

A prioritization framework for BRCA1/2 variants of uncertain significance identified by comprehensive genomic profiling.

A prioritization framework for BRCA1/2 variants of uncertain significance identified by comprehensive genomic profiling.

Journal: European journal of human genetics : EJHG

Published: September 30, 2025

Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients.

Utility of Serum HBV RNA Measurement During Nucleoside/Nucleotide Analog Therapy in Chronic Hepatitis B Patients.

Journal: International journal of molecular sciences

Published: September 21, 2025

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular Carcinoma.

Journal: Internal medicine (Tokyo, Japan)

Published: September 03, 2025

Do Asian patients with HCC derive greater benefit from anti-PD-L1 plus anti-CTLA-4 therapy?

Do Asian patients with HCC derive greater benefit from anti-PD-L1 plus anti-CTLA-4 therapy?

Journal: Hepatobiliary surgery and nutrition

Published: July 15, 2025

Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution.

Analysis of the treatment outcome of duodenal varices: A retrospective case series of 15 patients from a single institution.

Journal: DEN open

Published: March 05, 2025

Showing 1-12 of 154

Last Updated: 09/26/2026